禾川科技(688320.SH):新增了人形機器人、逆變、光伏儲能、精密導軌絲桿、直線電機、工業電機項目
格隆匯11月4日丨禾川科技(688320.SH)在互動平台表示,2022年末公司研發人數為493人,2023年年中研發人員薪酬為5,085萬元,為2023年1-6月逐月增加人數所致。公司主要技術人員及簡歷屬於公司機密,不便透露。公司未來研發方向仍聚焦於工業自動化領域,加大了新業務領域的研發投入,為攻佔各細分行業市場,提升創新能力,新增了人形機器人、逆變、光伏儲能、精密導軌絲桿、直線電機、工業電機項目,優化控制器、變頻器產品,開發細分行業解決方案應用控制系統。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.